Literature DB >> 24227882

Computed tomography surveillance scanning after lung cancer surgery: mathematical optimization of scanning interval based on tumour biology.

Michael Poullis1.   

Abstract

OBJECTIVES: To determine the optimal computed tomography (CT) scanning interval for the detection of a new primary lung cancer and recurrent disease, utilizing the known mathematical formula for tumour doubling.
METHODS: where: Ti interval time, Di initial diameter and Do final diameter. Three doubling times were utilized for demonstration of the principle, 30, 80 and 100 days.
RESULTS: A worst-case scenario for a doubling time of 30 days indicates that a 2-mm tumour will need 210 days (7 months) to reach 10 mm in diameter and 300 days (10 months) to reach 20 mm in diameter. Over a 5-year (60 months) follow-up period, this indicates that eight CT scans will be required if a threshold of 10 mm is desired or six if a threshold of 20 mm is desired. For an 80-day doubling time over a 5-year (60 months) follow-up period, three CT scans will be required if a threshold of 10 mm is desired or two if a threshold of 20 mm is desired and for a 100-day doubling time. Assuming complete histological clearance of the primary lung cancer and that recurrence occurs from a microscopic focus, a time period of 1700 days (56 months) is required to reach 10 mm in diameter.
CONCLUSIONS: The exact timing of interval CT scanning to detect recurrence and new primary tumour depends on philosophy; however, three monthly CT scanning is probably inappropriate, and scanning every 7 months is probably the shortest interval that is clinically useful, particularly for small-cell lung cancer in the first year after treatment. We recommend, based on mathematical modelling, a scanning interval post-potentially curative resection surgery for primary lung cancer of 18 months, which is different from the current guidelines on surveillance, for non-small-cell lung cancer.

Entities:  

Keywords:  CT scanning; Lung cancer

Mesh:

Year:  2013        PMID: 24227882      PMCID: PMC3895060          DOI: 10.1093/icvts/ivt449

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  17 in total

Review 1.  Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness.

Authors:  Bernardo H L Goulart; Mark E Bensink; David G Mummy; Scott D Ramsey
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

2.  Screening for lung cancer using low dose CT scanning: results of 2 year follow up.

Authors:  R MacRedmond; G McVey; M Lee; R W Costello; D Kenny; C Foley; P M Logan
Journal:  Thorax       Date:  2006-01       Impact factor: 9.139

3.  Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers.

Authors:  Rebecca M Lindell; Thomas E Hartman; Stephen J Swensen; James R Jett; David E Midthun; Henry D Tazelaar; Jayawant N Mandrekar
Journal:  Radiology       Date:  2007-02       Impact factor: 11.105

4.  Volume doubling time of lung cancers detected in a chest radiograph mass screening program: Comparison with CT screening.

Authors:  Maki Kanashiki; Takuji Tomizawa; Iwao Yamaguchi; Koichi Kurishima; Nobuyuki Hizawa; Hiroichi Ishikawa; Katsunori Kagohashi; Hiroaki Satoh
Journal:  Oncol Lett       Date:  2012-06-28       Impact factor: 2.967

5.  How do lung cancer specialists follow their patients with stage III non-small cell lung cancer (NSCLC) after definitive treatment? A short report.

Authors:  Perran Fulden Yumuk; Nazia Mohammed; Alexander P W M Maat; Christian Fink; Benedicte Marchal; Mary E R O'Brien
Journal:  Eur J Cancer       Date:  2012-05-26       Impact factor: 9.162

6.  Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers.

Authors:  Stefan Diederich; Dag Wormanns; Michael Semik; Michael Thomas; Horst Lenzen; Nikolaus Roos; Walter Heindel
Journal:  Radiology       Date:  2002-03       Impact factor: 11.105

7.  CT screening for lung cancer: five-year prospective experience.

Authors:  Stephen J Swensen; James R Jett; Thomas E Hartman; David E Midthun; Sumithra J Mandrekar; Shauna L Hillman; Anne-Marie Sykes; Gregory L Aughenbaugh; Aaron O Bungum; Katie L Allen
Journal:  Radiology       Date:  2005-02-04       Impact factor: 11.105

8.  Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group.

Authors:  T Arai; T Kuroishi; Y Saito; Y Kurita; T Naruke; M Kaneko
Journal:  Jpn J Clin Oncol       Date:  1994-08       Impact factor: 3.019

9.  Doubling time of lung cancer determined using three-dimensional volumetric software: comparison of squamous cell carcinoma and adenocarcinoma.

Authors:  Osamu Honda; Takeshi Johkoh; Junko Sekiguchi; Noriyuki Tomiyama; Naoki Mihara; Hiromitsu Sumikawa; Atsuo Inoue; Masahiro Yanagawa; Tadahisa Daimon; Meinoshin Okumura; Hironobu Nakamura
Journal:  Lung Cancer       Date:  2009-02-28       Impact factor: 5.705

10.  Small cell lung cancer doubling time and its effect on clinical presentation: a concise review.

Authors:  Kassem Harris; Inga Khachaturova; Basem Azab; Theodore Maniatis; Srujitha Murukutla; Michel Chalhoub; Hassan Hatoum; Thomas Kilkenny; Dany Elsayegh; Rabih Maroun; Homam Alkaied
Journal:  Clin Med Insights Oncol       Date:  2012-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.